In conclusion, the in vivo work on LPS- and CLP-induced sepsis mice demonstrates that CBP bromodomain maybe a therapeutic target for sepsis, and the most potent CBP inhibitor, SGC-CBP30, significantly rescued mice from the sepsis model. Here, CREBBP is linked to Sepsis.